Inobrodib is under clinical development by CellCentric and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to GlobalData, Phase II drugs for Relapsed Acute Myeloid Leukemia have a 20% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Inobrodib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Inobrodib (CCS-1477) is under development for the treatment of solid tumors including castrate-resistant prostate cancer, metastatic breast cancer, non-small cell lung cancer, hematological cancers including diffuse large B-Cell lymphoma, relapsed or refractory multiple myeloma, acute myeloid leukaemia, non-hodgkin lymphoma including peripheral T-cell lymphomas, myelodysplastic syndrome, lung cancer and bladder cancer. It is administered orally. The drug candidate acts by targeting E1A binding protein (p300) and CREB binding protein (CBP). p300/CBP collectively relates to histone acetyl transferase proteins.
CellCentric is a clinical-stage biotechnology company that develops novel small molecule inhibitors. The company develops p300/CBP small molecule inhibitors against cancer-driving genes. The company operates through its offices located in Oxford and Cheshire, the UK. CellCentric is headquartered in Cambridge, the UK.
For a complete picture of Inobrodib’s drug-specific PTSR and LoA scores, buy the report here.